Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Early-stage mechanistic study demonstrating a chemical modification strategy for cell-penetrating peptides in cell culture; no clinical outcomes or human data reported.
This is a narrative review of CRISPR-Cas9 delivery concepts for bladder cancer therapy with no original experimental data, clinical trial results, or comparative evidence.
A narrative review synthesizing recent advances in CRISPR delivery strategies across research and clinical contexts, offering state-of-the-art overview rather than novel empirical evidence or recommendations.
A comprehensive review synthesizing the state of mRNA cancer therapeutics across design, delivery, and clinical translation—expert framing rather than a new empirical finding.
A narrative review of preclinical and mechanistic studies proposing CRISPR-Cas13 as a therapeutic concept for HIV remission, without clinical trial data or definitive evidence of durable clinical benefit.
This is an exploratory in vitro proof-of-concept study of a novel nanoplatform combining siRNA and photothermal therapy; it demonstrates mechanism in cell models but lacks in vivo efficacy data, clinical translation, or direct comparison to standard antiviral therapy.
A narrative review of preclinical literature synthesizing nanocarrier design and CRISPR delivery mechanisms, raising research directions rather than reporting original empirical evidence or clinical outcomes.
Early-phase in vitro characterization of a novel drug delivery system in cell lines; demonstrates proof-of-concept but lacks in vivo validation, clinical endpoints, or comparison to standard therapies.